ALK 0 3 0 3 O
- 3 4 3 4 O
positive 4 12 4 12 O
NSCLC 13 18 13 18 B-cancer
, 18 19 18 19 O
neuroblastoma 20 33 20 33 B-cancer
, 33 34 33 34 O
and 35 38 35 38 O
childhood 39 48 39 48 O
tumors 49 55 49 55 B-cancer

Active 0 6 56 62 O
or 7 9 63 65 O
history 10 17 66 73 O
of 18 20 74 76 O
autoimmune 21 31 77 87 B-chronic_disease
disease 32 39 88 95 I-chronic_disease
or 40 42 96 98 O
immune 43 49 99 105 B-chronic_disease
deficiency 50 60 106 116 I-chronic_disease

Active 0 6 117 123 O
or 7 9 124 126 O
untreated 10 19 127 136 O
brain 20 25 137 142 B-cancer
metastases 26 36 143 153 I-cancer

Administration 0 14 154 168 O
of 15 17 169 171 O
strong 18 24 172 178 O
/ 24 25 178 179 O
potent 25 31 179 185 O
cytochrome 32 42 186 196 B-treatment
P3A4 43 47 197 201 I-treatment
( 48 49 202 203 I-treatment
CYP3A4 49 55 203 209 I-treatment
) 55 56 209 210 I-treatment
inhibitors 57 67 211 221 I-treatment
or 68 70 222 224 O
inducers 71 79 225 233 O
within 80 86 234 240 O
14 87 89 241 243 B-upper_bound
days 90 94 244 248 I-upper_bound
prior 95 100 249 254 I-upper_bound
to 101 103 255 257 O
the 104 107 258 261 O
first 108 113 262 267 O
dose 114 118 268 272 O
of 119 121 273 275 O
study 122 127 276 281 B-treatment
treatment 128 137 282 291 I-treatment
and 138 141 292 295 O
while 142 147 296 301 O
on 148 150 302 304 O
treatment 151 160 305 314 B-treatment
with 161 165 315 319 I-treatment
alectinib 166 175 320 329 I-treatment

All 0 3 330 333 O
non 4 7 334 337 O
- 7 8 337 338 O
hematological 8 21 338 351 O
adverse 22 29 352 359 O
events 30 36 360 366 O
related 37 44 367 374 O
to 45 47 375 377 O
any 48 51 378 381 O
prior 52 57 382 387 B-treatment
chemotherapy 58 70 388 400 I-treatment
, 70 71 400 401 O
surgery 72 79 402 409 B-treatment
, 79 80 409 410 O
or 81 83 411 413 O
radiotherapy 84 96 414 426 B-treatment
must 97 101 427 431 O
have 102 106 432 436 O
resolved 107 115 437 445 O
to 116 118 446 448 O
National 119 127 449 457 B-clinical_variable
Cancer 128 134 458 464 I-clinical_variable
Institute 135 144 465 474 I-clinical_variable
Common 145 151 475 481 I-clinical_variable
Terminology 152 163 482 493 I-clinical_variable
Criteria 164 172 494 502 I-clinical_variable
for 173 176 503 506 I-clinical_variable
Adverse 177 184 507 514 I-clinical_variable
Events 185 191 515 521 I-clinical_variable
( 192 193 522 523 I-clinical_variable
NCI 193 196 523 526 I-clinical_variable
CTCAE 197 202 527 532 I-clinical_variable
) 202 203 532 533 I-clinical_variable
Grade 204 209 534 539 I-clinical_variable
less 210 214 540 544 O
than 215 219 545 549 O
or 220 222 550 552 O
equal 223 228 553 558 O
to 229 231 559 561 O
( 232 233 562 563 O
≤ 233 234 563 564 O
) 234 235 564 565 O
2 236 237 566 567 B-upper_bound
prior 238 243 568 573 I-upper_bound
to 244 246 574 576 O
starting 247 255 577 585 O
therapy 256 263 586 593 O

Any 0 3 594 597 O
other 4 9 598 603 O
disease 10 17 604 611 O
, 17 18 611 612 O
metabolic 19 28 613 622 O
dysfunction 29 40 623 634 O
, 40 41 634 635 O
physical 42 50 636 644 O
examination 51 62 645 656 O
finding 63 70 657 664 O
, 70 71 664 665 O
or 72 74 666 668 O
clinical 75 83 669 677 O
laboratory 84 94 678 688 O
finding 95 102 689 696 O
that 103 107 697 701 O
contraindicates 108 123 702 717 O
the 124 127 718 721 O
use 128 131 722 725 O
of 132 134 726 728 O
an 135 137 729 731 O
investigational 138 153 732 747 B-allergy_name
drug 154 158 748 752 I-allergy_name
, 158 159 752 753 O
may 160 163 754 757 O
affect 164 170 758 764 O
the 171 174 765 768 O
interpretation 175 189 769 783 O
of 190 192 784 786 O
the 193 196 787 790 O
results 197 204 791 798 O
, 204 205 798 799 O
or 206 208 800 802 O
may 209 212 803 806 O
render 213 219 807 813 O
the 220 223 814 817 O
participant 224 235 818 829 O
at 236 238 830 832 O
high 239 243 833 837 O
risk 244 248 838 842 O
from 249 253 843 847 O
treatment 254 263 848 857 B-treatment
complications 264 277 858 871 O

Any 0 3 872 875 O
other 4 9 876 881 O
severe 10 16 882 888 O
acute 17 22 889 894 O
or 23 25 895 897 O
chronic 26 33 898 905 O
medical 34 41 906 913 B-chronic_disease
or 42 44 914 916 O
psychiatric 45 56 917 928 B-chronic_disease
condition 57 66 929 938 I-chronic_disease
or 67 69 939 941 O
laboratory 70 80 942 952 O
abnormality 81 92 953 964 O
that 93 97 965 969 O
may 98 101 970 973 O
increase 102 110 974 982 O
the 111 114 983 986 O
risk 115 119 987 991 O
associated 120 130 992 1002 O
with 131 135 1003 1007 O
study 136 141 1008 1013 O
participation 142 155 1014 1027 O
or 156 158 1028 1030 O
may 159 162 1031 1034 O
interfere 163 172 1035 1044 O
with 173 177 1045 1049 O
the 178 181 1050 1053 O
interpretation 182 196 1054 1068 O
of 197 199 1069 1071 O
study 200 205 1072 1077 O
results 206 213 1078 1085 O

Any 0 3 1086 1089 O
significant 4 15 1090 1101 O
cardiovascular 16 30 1102 1116 B-chronic_disease
events 31 37 1117 1123 I-chronic_disease
within 38 44 1124 1130 O
6 45 46 1131 1132 B-upper_bound
months 47 53 1133 1139 I-upper_bound
prior 54 59 1140 1145 I-upper_bound
to 60 62 1146 1148 O
study 63 68 1149 1154 O
entry 69 74 1155 1160 O

Asymptomatic 0 12 1161 1173 B-cancer
metastatic 13 23 1174 1184 I-cancer
lesions 24 31 1185 1192 O
that 32 36 1193 1197 O
would 37 42 1198 1203 O
likely 43 49 1204 1210 O
cause 50 55 1211 1216 O
functional 56 66 1217 1227 O
deficits 67 75 1228 1236 O
or 76 78 1237 1239 O
intractable 79 90 1240 1251 O
pain 91 95 1252 1256 O
with 96 100 1257 1261 O
further 101 108 1262 1269 O
growth 109 115 1270 1276 O
( 116 117 1277 1278 O
e.g. 117 121 1278 1282 O
, 121 122 1282 1283 O
epidural 123 131 1284 1292 B-cancer
metastasis 132 142 1293 1303 I-cancer
that 143 147 1304 1308 O
is 148 150 1309 1311 O
not 151 154 1312 1315 O
currently 155 164 1316 1325 O
associated 165 175 1326 1336 O
with 176 180 1337 1341 O
spinal 181 187 1342 1348 O
cord 188 192 1349 1353 O
compression 193 204 1354 1365 O
) 204 205 1365 1366 O
should 206 212 1367 1373 O
be 213 215 1374 1376 O
considered 216 226 1377 1387 O
for 227 230 1388 1391 O
loco 231 235 1392 1396 O
- 235 236 1396 1397 O
regional 236 244 1397 1405 O
therapy 245 252 1406 1413 B-treatment
if 253 255 1414 1416 O
appropriate 256 267 1417 1428 O
prior 268 273 1429 1434 O
to 274 276 1435 1437 O
enrollment 277 287 1438 1448 O

Availability 0 12 1449 1461 O
of 13 15 1462 1464 O
an 16 18 1465 1467 O
archival 19 27 1468 1476 O
or 28 30 1477 1479 O
new 31 34 1480 1483 O
pre 35 38 1484 1487 B-treatment
- 38 39 1487 1488 I-treatment
treatment 39 48 1488 1497 I-treatment
tissue 49 55 1498 1504 O
sample 56 62 1505 1511 O
is 63 65 1512 1514 O
required 66 74 1515 1523 O
if 75 77 1524 1526 O
molecular 78 87 1527 1536 O
testing 88 95 1537 1544 O
was 96 99 1545 1548 O
not 100 103 1549 1552 O
performed 104 113 1553 1562 O
by 114 116 1563 1565 O
Foundation 117 127 1566 1576 O
Medicine 128 136 1577 1585 O
. 136 137 1585 1586 O
Any 138 141 1587 1590 O
available 142 151 1591 1600 O
tumor 152 157 1601 1606 B-cancer
tissue 158 164 1607 1613 O
sample 165 171 1614 1620 O
can 172 175 1621 1624 O
be 176 178 1625 1627 O
submitted 179 188 1628 1637 O
. 188 189 1637 1638 O
The 190 193 1639 1642 O
tissue 194 200 1643 1649 O
sample 201 207 1650 1656 O
must 208 212 1657 1661 O
be 213 215 1662 1664 O
submitted 216 225 1665 1674 O
within 226 232 1675 1681 O
4 233 234 1682 1683 B-upper_bound
weeks 235 240 1684 1689 I-upper_bound
after 241 246 1690 1695 O
enrollment 247 257 1696 1706 O

Basal 0 5 1707 1712 B-cancer
cell 6 10 1713 1717 I-cancer
carcinoma 11 20 1718 1727 I-cancer
of 21 23 1728 1730 I-cancer
the 24 27 1731 1734 I-cancer
skin 28 32 1735 1739 I-cancer
, 32 33 1739 1740 O
medulloblastoma 34 49 1741 1756 B-cancer
, 49 50 1756 1757 O
small 51 56 1758 1763 B-cancer
- 56 57 1763 1764 I-cancer
cell 57 61 1764 1768 I-cancer
lung 62 66 1769 1773 I-cancer
cancer 67 73 1774 1780 I-cancer
, 73 74 1780 1781 O
or 75 77 1782 1784 O
hematologic 78 89 1785 1796 B-cancer
malignancies 90 102 1797 1809 I-cancer

Cancers 0 7 1810 1817 B-cancer
with 8 12 1818 1822 O
exon 13 17 1823 1827 O
20 18 20 1828 1830 O
mutations 21 30 1831 1840 O

Concurrent 0 10 1841 1851 O
administration 11 25 1852 1866 O
of 26 28 1867 1869 O
any 29 32 1870 1873 O
other 33 38 1874 1879 O
anti 39 43 1880 1884 B-treatment
- 43 44 1884 1885 I-treatment
cancer 44 50 1885 1891 I-treatment
therapy 51 58 1892 1899 I-treatment
( 59 60 1900 1901 O
except 60 66 1901 1907 O
male 67 71 1908 1912 B-gender
participants 72 84 1913 1925 I-gender
with 85 89 1926 1930 O
prostate 90 98 1931 1939 B-cancer
cancer 99 105 1940 1946 I-cancer
receiving 106 115 1947 1956 O
androgen 116 124 1957 1965 B-treatment
blockade 125 133 1966 1974 I-treatment
): 133 135 1974 1976 O
Bisphosphonates 136 151 1977 1992 B-treatment
and 152 155 1993 1996 O
denosumab 156 165 1997 2006 B-treatment
are 166 169 2007 2010 O
allowed 170 177 2011 2018 O
; 177 178 2018 2019 O
Most 179 183 2020 2024 O
recent 184 190 2025 2031 O
anti 191 195 2032 2036 O
- 195 196 2036 2037 O
cancer 196 202 2037 2043 O
therapy 203 210 2044 2051 O
≤28 211 214 2052 2055 O
days 215 219 2056 2060 I-upper_bound
and 220 223 2061 2064 O
have 224 228 2065 2069 O
not 229 232 2070 2073 O
recovered 233 242 2074 2083 O
from 243 247 2084 2088 O
the 248 251 2089 2092 O
side 252 256 2093 2097 O
effects 257 264 2098 2105 O
, 264 265 2105 2106 O
excluding 266 275 2107 2116 O
alopecia 276 284 2117 2125 B-chronic_disease
; 284 285 2125 2126 O
Radiation 286 295 2127 2136 B-treatment
therapy 296 303 2137 2144 I-treatment
within 304 310 2145 2151 O
≤14 311 314 2152 2155 O
days 315 319 2156 2160 I-upper_bound

Eastern 0 7 2161 2168 B-clinical_variable
Cooperative 8 19 2169 2180 I-clinical_variable
Oncology 20 28 2181 2189 I-clinical_variable
Group 29 34 2190 2195 I-clinical_variable
Performance 35 46 2196 2207 I-clinical_variable
Status 47 53 2208 2214 I-clinical_variable
( 54 55 2215 2216 I-clinical_variable
ECOG 55 59 2216 2220 I-clinical_variable
PS 60 62 2221 2223 I-clinical_variable
) 62 63 2223 2224 I-clinical_variable
score 64 69 2225 2230 I-clinical_variable
of 70 72 2231 2233 O
0 73 74 2234 2235 B-lower_bound
or 75 77 2236 2238 O
1 78 79 2239 2240 B-upper_bound

For 0 3 2241 2244 O
participants 4 16 2245 2257 O
screened 17 25 2258 2266 O
using 26 31 2267 2272 O
a 32 33 2273 2274 O
blood 34 39 2275 2280 O
assay 40 45 2281 2286 O
: 45 46 2286 2287 O
obtain 47 53 2288 2294 O
tissue 54 60 2295 2301 O
- 60 61 2301 2302 O
based 61 66 2302 2307 O
testing 67 74 2308 2315 O
result 75 81 2316 2322 O
confirming 82 92 2323 2333 O
study 93 98 2334 2339 O
eligibility 99 110 2340 2351 O
( 111 112 2352 2353 O
within 112 118 2353 2359 O
first 119 124 2360 2365 B-upper_bound
4 125 126 2366 2367 I-upper_bound
weeks 127 132 2368 2373 I-upper_bound
after 133 138 2374 2379 O
enrollment 139 149 2380 2390 O
) 149 150 2390 2391 O

For 0 3 2392 2395 O
patients 4 12 2396 2404 O
enrolling 13 22 2405 2414 O
in 23 25 2415 2417 O
the 26 29 2418 2421 O
atezolizumab 30 42 2422 2434 B-treatment
arm 43 46 2435 2438 I-treatment
, 46 47 2438 2439 O
ECOG 48 52 2440 2444 B-clinical_variable
score 53 58 2445 2450 I-clinical_variable
must 59 63 2451 2455 O
be 64 66 2456 2458 O
documented 67 77 2459 2469 O
within 78 84 2470 2476 O
7 85 86 2477 2478 B-upper_bound
days 87 91 2479 2483 I-upper_bound
prior 92 97 2484 2489 I-upper_bound
to 98 100 2490 2492 O
first 101 106 2493 2498 B-treatment
treatment 107 116 2499 2508 I-treatment
and 117 120 2509 2512 O
confirmation 121 133 2513 2525 O
of 134 136 2526 2528 O
ECOG 137 141 2529 2533 O
PS 142 144 2534 2536 O
must 145 149 2537 2541 O
be 150 152 2542 2544 O
entered 153 160 2545 2552 O
into 161 165 2553 2557 O
the 166 169 2558 2561 O
interactive 170 181 2562 2573 O
web 182 185 2574 2577 O
response 186 194 2578 2586 O
system 195 201 2587 2593 O
[ 202 203 2594 2595 O
IWRS 203 207 2595 2599 O
] 207 208 2599 2600 O
prior 209 214 2601 2606 O
to 215 217 2607 2609 O
initiation 218 228 2610 2620 O
of 229 231 2621 2623 O
treatment 232 241 2624 2633 O

For 0 3 2634 2637 O
patients 4 12 2638 2646 O
where 13 18 2647 2652 O
molecular 19 28 2653 2662 O
testing 29 36 2663 2670 O
was 37 40 2671 2674 O
not 41 44 2675 2678 O
performed 45 54 2679 2688 O
using 55 60 2689 2694 O
Foundation 61 71 2695 2705 O
Medicine 72 80 2706 2714 O
, 80 81 2714 2715 O
submission 82 92 2716 2726 O
of 93 95 2727 2729 O
an 96 98 2730 2732 O
archival 99 107 2733 2741 O
or 108 110 2742 2744 O
new 111 114 2745 2748 O
pretreatment 115 127 2749 2761 O
tissue 128 134 2762 2768 O
sample 135 141 2769 2775 O
is 142 144 2776 2778 O
mandatory 145 154 2779 2788 O
. 154 155 2788 2789 O
For 156 159 2790 2793 O
patients 160 168 2794 2802 O
where 169 174 2803 2808 O
molecular 175 184 2809 2818 O
testing 185 192 2819 2826 O
was 193 196 2827 2830 O
performed 197 206 2831 2840 O
using 207 212 2841 2846 O
Foundation 213 223 2847 2857 O
Medicine 224 232 2858 2866 O
, 232 233 2866 2867 O
submission 234 244 2868 2878 O
of 245 247 2879 2881 O
an 248 250 2882 2884 O
archival 251 259 2885 2893 O
or 260 262 2894 2896 O
new 263 266 2897 2900 O
pretreatment 267 279 2901 2913 O
tissue 280 286 2914 2920 O
sample 287 293 2921 2927 O
is 294 296 2928 2930 O
required 297 305 2931 2939 O
, 305 306 2939 2940 O
if 307 309 2941 2943 O
available 310 319 2944 2953 O
. 319 320 2953 2954 O
The 321 324 2955 2958 O
tissue 325 331 2959 2965 O
sample 332 338 2966 2972 O
must 339 343 2973 2977 O
be 344 346 2978 2980 O
submitted 347 356 2981 2990 O
within 357 363 2991 2997 O
4 364 365 2998 2999 B-upper_bound
weeks 366 371 3000 3005 I-upper_bound
after 372 377 3006 3011 I-upper_bound
enrollment 378 388 3012 3022 O

Histologically 0 14 3023 3037 O
documented 15 25 3038 3048 O
metastatic 26 36 3049 3059 B-cancer
cancer 37 43 3060 3066 I-cancer
( 44 45 3067 3068 O
solid 45 50 3068 3073 B-cancer
tumors 51 57 3074 3080 I-cancer
, 57 58 3080 3081 O
not 59 62 3082 3085 O
including 63 72 3086 3095 O
hematologic 73 84 3096 3107 B-cancer
malignancies 85 97 3108 3120 I-cancer
) 97 98 3120 3121 O

History 0 7 3122 3129 O
of 8 10 3130 3132 O
carcinomatous 11 24 3133 3146 B-cancer
meningitis 25 35 3147 3157 I-cancer

History 0 7 3158 3165 O
of 8 10 3166 3168 O
congenital 11 21 3169 3179 O
long 22 26 3180 3184 B-chronic_disease
QT 27 29 3185 3187 I-chronic_disease
syndrome 30 38 3188 3196 I-chronic_disease
or 39 41 3197 3199 O
mean 42 46 3200 3204 O
( 47 48 3205 3206 O
average 48 55 3206 3213 O
of 56 58 3214 3216 O
triplicate 59 69 3217 3227 O
measurements 70 82 3228 3240 O
) 82 83 3240 3241 O
corrected 84 93 3242 3251 B-clinical_variable
QT 94 96 3252 3254 I-clinical_variable
( 97 98 3255 3256 I-clinical_variable
QTc 98 101 3256 3259 I-clinical_variable
) 101 102 3259 3260 I-clinical_variable
measured 103 111 3261 3269 I-clinical_variable
using 112 117 3270 3275 O
Fridericia 118 128 3276 3286 O
's 128 130 3286 3288 O
method 131 137 3289 3295 O
≥450 138 142 3296 3300 O
millisecond 143 154 3301 3312 I-lower_bound
( 155 156 3313 3314 I-lower_bound
ms 156 158 3314 3316 I-lower_bound
) 158 159 3316 3317 I-lower_bound
at 160 162 3318 3320 O
baseline 163 171 3321 3329 O
or 172 174 3330 3332 O
uncorrectable 175 188 3333 3346 O
abnormalities 189 202 3347 3360 O
in 203 205 3361 3363 O
serum 206 211 3364 3369 O
electrolytes 212 224 3370 3382 O
( 225 226 3383 3384 O
sodium 226 232 3384 3390 O
, 232 233 3390 3391 O
potassium 234 243 3392 3401 O
, 243 244 3401 3402 O
calcium 245 252 3403 3410 O
, 252 253 3410 3411 O
magnesium 254 263 3412 3421 O
, 263 264 3421 3422 O
phosphorus 265 275 3423 3433 O
) 275 276 3433 3434 O

History 0 7 3435 3442 O
of 8 10 3443 3445 O
idiopathic 11 21 3446 3456 B-chronic_disease
pulmonary 22 31 3457 3466 I-chronic_disease
fibrosis 32 40 3467 3475 I-chronic_disease
, 40 41 3475 3476 O
organizing 42 52 3477 3487 B-chronic_disease
pneumonia 53 62 3488 3497 I-chronic_disease
( 63 64 3498 3499 O
e.g. 64 68 3499 3503 O
, 68 69 3503 3504 O
bronchiolitis 70 83 3505 3518 B-chronic_disease
obliterans 84 94 3519 3529 I-chronic_disease
) 94 95 3529 3530 O
, 95 96 3530 3531 O
drug 97 101 3532 3536 B-chronic_disease
- 101 102 3536 3537 I-chronic_disease
induced 102 109 3537 3544 I-chronic_disease
pneumonitis 110 121 3545 3556 I-chronic_disease
, 121 122 3556 3557 O
or 123 125 3558 3560 O
idiopathic 126 136 3561 3571 B-chronic_disease
pneumonitis 137 148 3572 3583 I-chronic_disease
, 148 149 3583 3584 O
or 150 152 3585 3587 O
evidence 153 161 3588 3596 O
of 162 164 3597 3599 O
active 165 171 3600 3606 O
pneumonitis 172 183 3607 3618 O
on 184 186 3619 3621 O
screening 187 196 3622 3631 O
chest 197 202 3632 3637 O
computed 203 211 3638 3646 B-treatment
tomography 212 222 3647 3657 I-treatment
( 223 224 3658 3659 I-treatment
CT 224 226 3659 3661 I-treatment
) 226 227 3661 3662 I-treatment
scan 228 232 3663 3667 I-treatment

History 0 7 3668 3675 O
of 8 10 3676 3678 O
leptomeningeal 11 25 3679 3693 B-cancer
disease 26 33 3694 3701 I-cancer

History 0 7 3702 3709 O
of 8 10 3710 3712 O
or 11 13 3713 3715 O
evidence 14 22 3716 3724 O
of 23 25 3725 3727 O
retinal 26 33 3728 3735 B-chronic_disease
pathology 34 43 3736 3745 I-chronic_disease
on 44 46 3746 3748 O
ophthalmologic 47 61 3749 3763 O
examination 62 73 3764 3775 O
that 74 78 3776 3780 O
is 79 81 3781 3783 O
considered 82 92 3784 3794 O
a 93 94 3795 3796 O
risk 95 99 3797 3801 O
factor 100 106 3802 3808 O
for 107 110 3809 3812 O
neurosensory 111 123 3813 3825 O
retinal 124 131 3826 3833 O
detachment 132 142 3834 3844 O
, 142 143 3844 3845 O
retinal 144 151 3846 3853 B-chronic_disease
vein 152 156 3854 3858 I-chronic_disease
occlusion 157 166 3859 3868 I-chronic_disease
( 167 168 3869 3870 I-chronic_disease
RVO 168 171 3870 3873 I-chronic_disease
) 171 172 3873 3874 I-chronic_disease
, 172 173 3874 3875 O
or 174 176 3876 3878 O
neovascular 177 188 3879 3890 B-chronic_disease
macular 189 196 3891 3898 I-chronic_disease
degeneration 197 209 3899 3911 I-chronic_disease

History 0 7 3912 3919 O
of 8 10 3920 3922 O
other 11 16 3923 3928 O
malignancy 17 27 3929 3939 B-cancer
within 28 34 3940 3946 O
5 35 36 3947 3948 B-upper_bound
years 37 42 3949 3954 I-upper_bound
prior 43 48 3955 3960 I-upper_bound
to 49 51 3961 3963 O
screening 52 61 3964 3973 O
, 61 62 3973 3974 O
with 63 67 3975 3979 O
the 68 71 3980 3983 O
exception 72 81 3984 3993 O
of 82 84 3994 3996 O
those 85 90 3997 4002 O
with 91 95 4003 4007 O
a 96 97 4008 4009 O
negligible 98 108 4010 4020 O
risk 109 113 4021 4025 O
of 114 116 4026 4028 O
metastasis 117 127 4029 4039 B-cancer
or 128 130 4040 4042 O
death 131 136 4043 4048 O
, 136 137 4048 4049 O
such 138 142 4050 4054 O
as 143 145 4055 4057 O
adequately 146 156 4058 4068 O
treated 157 164 4069 4076 O
carcinoma 165 174 4077 4086 B-cancer
in 175 177 4087 4089 I-cancer
situ 178 182 4090 4094 I-cancer
of 183 185 4095 4097 I-cancer
the 186 189 4098 4101 I-cancer
cervix 190 196 4102 4108 I-cancer
, 196 197 4108 4109 O
non 198 201 4110 4113 B-cancer
- 201 202 4113 4114 I-cancer
melanoma 202 210 4114 4122 I-cancer
skin 211 215 4123 4127 I-cancer
carcinoma 216 225 4128 4137 I-cancer
, 225 226 4137 4138 O
localized 227 236 4139 4148 B-cancer
prostate 237 245 4149 4157 I-cancer
cancer 246 252 4158 4164 I-cancer
, 252 253 4164 4165 O
ductal 254 260 4166 4172 B-cancer
carcinoma 261 270 4173 4182 I-cancer
in 271 273 4183 4185 I-cancer
situ 274 278 4186 4190 I-cancer
, 278 279 4190 4191 O
or 280 282 4192 4194 O
Stage 283 288 4195 4200 B-cancer
I 289 290 4201 4202 I-cancer
uterine 291 298 4203 4210 I-cancer
cancer 299 305 4211 4217 I-cancer

History 0 7 4218 4225 O
of 8 10 4226 4228 O
severe 11 17 4229 4235 O
allergic 18 26 4236 4244 O
, 26 27 4244 4245 O
anaphylactic 28 40 4246 4258 O
, 40 41 4258 4259 O
or 42 44 4260 4262 O
other 45 50 4263 4268 O
hypersensitivity 51 67 4269 4285 O
reactions 68 77 4286 4295 O
to 78 80 4296 4298 O
chimeric 81 89 4299 4307 B-allergy_name
or 90 92 4308 4310 O
humanized 93 102 4311 4320 B-allergy_name
antibodies 103 113 4321 4331 I-allergy_name
or 114 116 4332 4334 O
fusion 117 123 4335 4341 B-allergy_name
proteins 124 132 4342 4350 I-allergy_name

History 0 7 4351 4358 O
or 8 10 4359 4361 O
presence 11 19 4362 4370 O
of 20 22 4371 4373 O
clinically 23 33 4374 4384 O
significant 34 45 4385 4396 O
ventricular 46 57 4397 4408 B-clinical_variable
or 58 60 4409 4411 O
atrial 61 67 4412 4418 B-clinical_variable
dysrhythmia 68 79 4419 4430 I-clinical_variable
> 80 81 4431 4432 O
Grade 81 86 4432 4437 B-chronic_disease
2 87 88 4438 4439 I-chronic_disease
per 89 92 4440 4443 O
NCI 93 96 4444 4447 O
CTCAE 97 102 4448 4453 O
v4.0 103 107 4454 4458 O

Known 0 5 4459 4464 O
allergy 6 13 4465 4472 O
or 14 16 4473 4475 O
hypersensitivity 17 33 4476 4492 O
to 34 36 4493 4495 O
any 37 40 4496 4499 O
component 41 50 4500 4509 B-allergy_name
of 51 53 4510 4512 I-allergy_name
the 54 57 4513 4516 I-allergy_name
atezolizumab 58 70 4517 4529 I-allergy_name
formulation 71 82 4530 4541 I-allergy_name

Known 0 5 4542 4547 O
hypersensitivity 6 22 4548 4564 O
to 23 25 4565 4567 O
biopharmaceutical 26 43 4568 4585 B-allergy_name
agents 44 50 4586 4592 I-allergy_name
produced 51 59 4593 4601 O
in 60 62 4602 4604 O
Chinese 63 70 4605 4612 O
hamster 71 78 4613 4620 O
ovary 79 84 4621 4626 O
cells 85 90 4627 4632 O

LVEF 0 4 4633 4637 B-clinical_variable
below 5 10 4638 4643 O
institutional 11 24 4644 4657 O
lower 25 30 4658 4663 B-clinical_variable
level 31 36 4664 4669 I-clinical_variable
of 37 39 4670 4672 I-clinical_variable
normal 40 46 4673 4679 I-clinical_variable
( 47 48 4680 4681 I-clinical_variable
LLN 48 51 4681 4684 I-clinical_variable
) 51 52 4684 4685 I-clinical_variable
or 53 55 4686 4688 O
below 56 61 4689 4694 O
50 62 64 4695 4697 B-upper_bound
% 64 65 4697 4698 I-upper_bound
, 65 66 4698 4699 O
whichever 67 76 4700 4709 O
is 77 79 4710 4712 O
lower 80 85 4713 4718 O

Left 0 4 4719 4723 B-clinical_variable
ventricular 5 16 4724 4735 I-clinical_variable
ejection 17 25 4736 4744 I-clinical_variable
fraction 26 34 4745 4753 I-clinical_variable
( 35 36 4754 4755 I-clinical_variable
LVEF 36 40 4755 4759 I-clinical_variable
) 40 41 4759 4760 I-clinical_variable
greater 42 49 4761 4768 O
than 50 54 4769 4773 O
( 55 56 4774 4775 O
> 56 57 4775 4776 O
) 57 58 4776 4777 O
50 59 61 4778 4780 B-lower_bound
percent 62 69 4781 4788 I-lower_bound
( 70 71 4789 4790 I-lower_bound
% 71 72 4790 4791 I-lower_bound
) 72 73 4791 4792 I-lower_bound
or 74 76 4793 4795 O
above 77 82 4796 4801 O
the 83 86 4802 4805 O
lower 87 92 4806 4811 O
limit 93 98 4812 4817 O
of 99 101 4818 4820 O
the 102 105 4821 4824 O
institutional 106 119 4825 4838 O
normal 120 126 4839 4845 O
range 127 132 4846 4851 O
, 132 133 4851 4852 O
whichever 134 143 4853 4862 O
is 144 146 4863 4865 O
lower 147 152 4866 4871 O

Life 0 4 4872 4876 B-clinical_variable
expectancy 5 15 4877 4887 I-clinical_variable
greater 16 23 4888 4895 O
than 24 28 4896 4900 O
or 29 31 4901 4903 O
equal 32 37 4904 4909 O
to 38 40 4910 4912 O
( 41 42 4913 4914 O
≥ 42 43 4914 4915 O
) 43 44 4915 4916 O
12 45 47 4917 4919 B-lower_bound
weeks 48 53 4920 4925 I-lower_bound

Major 0 5 4926 4931 B-treatment
surgical 6 14 4932 4940 I-treatment
procedure 15 24 4941 4950 I-treatment
other 25 30 4951 4956 O
than 31 35 4957 4961 O
for 36 39 4962 4965 O
diagnosis 40 49 4966 4975 O
within 50 56 4976 4982 O
4 57 58 4983 4984 B-upper_bound
weeks 59 64 4985 4990 I-upper_bound
prior 65 70 4991 4996 I-upper_bound
to 71 73 4997 4999 O
initiation 74 84 5000 5010 O
of 85 87 5011 5013 O
study 88 93 5014 5019 O
treatment 94 103 5020 5029 B-treatment
, 103 104 5029 5030 O
or 105 107 5031 5033 O
anticipation 108 120 5034 5046 O
of 121 123 5047 5049 O
need 124 128 5050 5054 O
for 129 132 5055 5058 O
a 133 134 5059 5060 O
major 135 140 5061 5066 B-treatment
surgical 141 149 5067 5075 I-treatment
procedure 150 159 5076 5085 I-treatment
during 160 166 5086 5092 O
the 167 170 5093 5096 O
course 171 177 5097 5103 O
of 178 180 5104 5106 O
the 181 184 5107 5110 O
study 185 190 5111 5116 O

Malignant 0 9 5117 5126 B-cancer
melanoma 10 18 5127 5135 I-cancer
, 18 19 5135 5136 O
papillary 20 29 5137 5146 B-cancer
thyroid 30 37 5147 5154 I-cancer
cancer 38 44 5155 5161 I-cancer
, 44 45 5161 5162 O
colorectal 46 56 5163 5173 B-cancer
cancer 57 63 5174 5180 I-cancer
, 63 64 5180 5181 O
or 65 67 5182 5184 O
hematologic 68 79 5185 5196 B-cancer
malignancy 80 90 5197 5207 I-cancer
including 91 100 5208 5217 O
multiple 101 109 5218 5226 O
myeloma 110 117 5227 5234 B-cancer

Measurable 0 10 5235 5245 B-chronic_disease
disease 11 18 5246 5253 I-chronic_disease
by 19 21 5254 5256 O
RECIST 22 28 5257 5263 O
v1.1 29 33 5264 5268 O

Molecular 0 9 5269 5278 O
testing 10 17 5279 5286 O
results 18 25 5287 5294 O
from 26 30 5295 5299 O
CLIA 31 35 5300 5304 O
- 35 36 5304 5305 O
certified 36 45 5305 5314 O
laboratories 46 58 5315 5327 O
( 59 60 5328 5329 O
using 60 65 5329 5334 O
tissue 66 72 5335 5341 O
and/or 73 79 5342 5348 O
blood 80 85 5349 5354 O
) 85 86 5354 5355 O
demonstrating 87 100 5356 5369 O
BRAF 101 105 5370 5374 O
V600 106 110 5375 5379 O
mutations 111 120 5380 5389 O
a 121 122 5390 5391 O
) 122 123 5391 5392 O
For 124 127 5393 5396 O
participants 128 140 5397 5409 O
screened 141 149 5410 5418 O
using 150 155 5419 5424 O
a 156 157 5425 5426 O
blood 158 163 5427 5432 O
assay 164 169 5433 5438 O
: 169 170 5438 5439 O
obtain 171 177 5440 5446 O
tissue 178 184 5447 5453 O
- 184 185 5453 5454 O
based 185 190 5454 5459 O
testing 191 198 5460 5467 O
result 199 205 5468 5474 O
confirming 206 216 5475 5485 O
study 217 222 5486 5491 O
eligibility 223 234 5492 5503 O
( 235 236 5504 5505 O
within 236 242 5505 5511 O
first 243 248 5512 5517 B-upper_bound
4 249 250 5518 5519 I-upper_bound
weeks 251 256 5520 5525 I-upper_bound
after 257 262 5526 5531 I-upper_bound
enrollment 263 273 5532 5542 O
) 273 274 5542 5543 O

Molecular 0 9 5544 5553 B-treatment
testing 10 17 5554 5561 I-treatment
results 18 25 5562 5569 O
from 26 30 5570 5574 O
CLIA 31 35 5575 5579 O
- 35 36 5579 5580 O
certified 36 45 5580 5589 O
laboratories 46 58 5590 5602 O
( 59 60 5603 5604 O
using 60 65 5604 5609 O
tissue 66 72 5610 5616 O
and/or 73 79 5617 5623 O
blood 80 85 5624 5629 O
) 85 86 5629 5630 O
demonstrating 87 100 5631 5644 O
EGFR 101 105 5645 5649 O
- 105 106 5649 5650 O
activating 106 116 5650 5660 O
mutations 117 126 5661 5670 O

Molecular 0 9 5671 5680 O
testing 10 17 5681 5688 O
results 18 25 5689 5696 O
from 26 30 5697 5701 O
CLIA 31 35 5702 5706 O
- 35 36 5706 5707 O
certified 36 45 5707 5716 O
laboratories 46 58 5717 5729 O
( 59 60 5730 5731 O
using 60 65 5731 5736 O
tissue 66 72 5737 5743 O
and/or 73 79 5744 5750 O
blood 80 85 5751 5756 O
) 85 86 5756 5757 O
demonstrating 87 100 5758 5771 O
anaplastic 101 111 5772 5782 O
lymphoma 112 120 5783 5791 O
kinase 121 127 5792 5798 O
( 128 129 5799 5800 O
ALK 129 132 5800 5803 O
) 132 133 5803 5804 O
gene 134 138 5805 5809 O
rearrangements 139 153 5810 5824 O
, 153 154 5824 5825 O
ALK 155 158 5826 5829 O
mutations 159 168 5830 5839 O
, 168 169 5839 5840 O
ALK 170 173 5841 5844 O
copy 174 178 5845 5849 O
number 179 185 5850 5856 O
gain 186 190 5857 5861 O
or 191 193 5862 5864 O
( 194 195 5865 5866 O
for 195 198 5866 5869 O
melanoma 199 207 5870 5878 B-cancer
only 208 212 5879 5883 O
) 212 213 5883 5884 O
increased 214 223 5885 5894 O
ALK 224 227 5895 5898 O
expression 228 238 5899 5909 O
or 239 241 5910 5912 O
presence 242 250 5913 5921 O
of 251 253 5922 5924 O
ALK 254 257 5925 5928 O
- 257 258 5928 5929 O
alternative 258 269 5929 5940 O
transcription 270 283 5941 5954 O
initiation 284 294 5955 5965 O
transcript 295 305 5966 5976 O
( 306 307 5977 5978 O
ALKATI 307 313 5978 5984 O
) 313 314 5984 5985 O
a 315 316 5986 5987 O
) 316 317 5987 5988 O
For 318 321 5989 5992 O
participants 322 334 5993 6005 O
screened 335 343 6006 6014 O
using 344 349 6015 6020 O
a 350 351 6021 6022 O
blood 352 357 6023 6028 O
assay 358 363 6029 6034 O
: 363 364 6034 6035 O
obtain 365 371 6036 6042 O
tissue 372 378 6043 6049 O
- 378 379 6049 6050 O
based 379 384 6050 6055 O
testing 385 392 6056 6063 O
result 393 399 6064 6070 O
confirming 400 410 6071 6081 O
study 411 416 6082 6087 O
eligibility 417 428 6088 6099 O
( 429 430 6100 6101 O
within 430 436 6101 6107 O
first 437 442 6108 6113 O
4 443 444 6114 6115 B-upper_bound
weeks 445 450 6116 6121 I-upper_bound
after 451 456 6122 6127 I-upper_bound
enrollment 457 467 6128 6138 O
) 467 468 6138 6139 O

Molecular 0 9 6140 6149 O
testing 10 17 6150 6157 O
results 18 25 6158 6165 O
from 26 30 6166 6170 O
CLIA 31 35 6171 6175 O
- 35 36 6175 6176 O
certified 36 45 6176 6185 O
laboratories 46 58 6186 6198 O
( 59 60 6199 6200 O
using 60 65 6200 6205 O
tissue 66 72 6206 6212 O
) 72 73 6212 6213 O
demonstrating 74 87 6214 6227 O
elevated 88 96 6228 6236 O
tissue 97 103 6237 6243 O
tumor 104 109 6244 6249 O
mutational 110 120 6250 6260 O
burden 121 127 6261 6267 O
( 128 129 6268 6269 O
tTMB 129 133 6269 6273 B-clinical_variable
≥10 134 137 6274 6277 O
mutations/ 138 148 6278 6288 O
Megabase 149 157 6289 6297 B-clinical_variable
[ 158 159 6298 6299 I-clinical_variable
Mb 159 161 6299 6301 I-clinical_variable
] 161 162 6301 6302 I-clinical_variable
) 162 163 6302 6303 O

Molecular 0 9 6304 6313 O
testing 10 17 6314 6321 O
results 18 25 6322 6329 O
from 26 30 6330 6334 O
clinical 31 39 6335 6343 O
laboratory 40 50 6344 6354 O
improvement 51 62 6355 6366 O
amendments 63 73 6367 6377 O
( 74 75 6378 6379 O
CLIA)-certified 75 90 6379 6394 O
laboratories 91 103 6395 6407 O
( 104 105 6408 6409 O
using 105 110 6409 6414 O
tissue 111 117 6415 6421 O
and/or 118 124 6422 6428 O
blood 125 130 6429 6434 O
) 130 131 6434 6435 O
demonstrating 132 145 6436 6449 O
HER2 146 150 6450 6454 O
overexpression 151 165 6455 6469 O
or 166 168 6470 6472 O
amplification 169 182 6473 6486 O
. 182 183 6486 6487 O
Participants 184 196 6488 6500 O
must 197 201 6501 6505 O
have 202 206 6506 6510 O
one 207 210 6511 6514 B-lower_bound
of 211 213 6515 6517 O
the 214 217 6518 6521 O
following 218 227 6522 6531 O
tumor 228 233 6532 6537 B-cancer
types 234 239 6538 6543 O
: 239 240 6543 6544 O
biliary 241 248 6545 6552 B-cancer
cancer 249 255 6553 6559 I-cancer
, 255 256 6559 6560 O
salivary 257 265 6561 6569 B-cancer
cancer 266 272 6570 6576 I-cancer
, 272 273 6576 6577 O
or 274 276 6578 6580 O
bladder 277 284 6581 6588 B-cancer
cancer 285 291 6589 6595 I-cancer

No 0 2 6596 6598 O
previous 3 11 6599 6607 B-treatment
treatment 12 21 6608 6617 I-treatment
with 22 26 6618 6622 O
the 27 30 6623 6626 O
specific 31 39 6627 6635 O
assigned 40 48 6636 6644 O
study 49 54 6645 6650 O
drug 55 59 6651 6655 O
or 60 62 6656 6658 O
any 63 66 6659 6662 O
other 67 72 6663 6668 O
drug 73 77 6669 6673 O
sharing 78 85 6674 6681 O
the 86 89 6682 6685 O
same 90 94 6686 6690 O
target 95 101 6691 6697 O

Non 0 3 6698 6701 B-cancer
- 3 4 6701 6702 I-cancer
small 4 9 6702 6707 I-cancer
cell 10 14 6708 6712 I-cancer
lung 15 19 6713 6717 I-cancer
cancer 20 26 6718 6724 I-cancer
( 27 28 6725 6726 I-cancer
NSCLC 28 33 6726 6731 I-cancer
) 33 34 6731 6732 I-cancer
or 35 37 6733 6735 O
pancreatic 38 48 6736 6746 B-cancer
cancer 49 55 6747 6753 I-cancer
identified 56 66 6754 6764 O
by 67 69 6765 6767 O
exon 70 74 6768 6772 O
19 75 77 6773 6775 O
deletions 78 87 6776 6785 O
or 88 90 6786 6788 O
exon 91 95 6789 6793 O
21 96 98 6794 6796 O
L858R 99 104 6797 6802 O
substitution 105 117 6803 6815 O
mutations 118 127 6816 6825 O

Participants 0 12 6826 6838 O
who 13 16 6839 6842 O
have 17 21 6843 6847 O
received 22 30 6848 6856 O
standard 31 39 6857 6865 B-treatment
first 40 45 6866 6871 I-treatment
- 45 46 6871 6872 I-treatment
line 46 50 6872 6876 I-treatment
therapy 51 58 6877 6884 I-treatment
for 59 62 6885 6888 O
metastatic 63 73 6889 6899 O
cancer 74 80 6900 6906 B-cancer
( 81 82 6907 6908 O
except 82 88 6908 6914 O
for 89 92 6915 6918 O
the 93 96 6919 6922 O
tumors 97 103 6923 6929 B-cancer
for 104 107 6930 6933 O
which 108 113 6934 6939 O
no 114 116 6940 6942 O
first 117 122 6943 6948 O
- 122 123 6948 6949 O
line 123 127 6949 6953 O
therapy 128 135 6954 6961 O
exists 136 142 6962 6968 O
) 142 143 6968 6969 O
and 144 147 6970 6973 O
in 148 150 6974 6976 O
whom 151 155 6977 6981 O
a 156 157 6982 6983 O
trial 158 163 6984 6989 O
of 164 166 6990 6992 O
targeted 167 175 6993 7001 O
therapy 176 183 7002 7009 O
is 184 186 7010 7012 O
considered 187 197 7013 7023 O
the 198 201 7024 7027 O
best 202 206 7028 7032 O
available 207 216 7033 7042 O
treatment 217 226 7043 7052 B-treatment
option 227 233 7053 7059 O
. 233 234 7059 7060 O
Eligible 235 243 7061 7069 O
participants 244 256 7070 7082 O
should 257 263 7083 7089 O
not 264 267 7090 7093 O
have 268 272 7094 7098 O
available 273 282 7099 7108 O
therapies 283 292 7109 7118 B-treatment
that 293 297 7119 7123 O
will 298 302 7124 7128 O
convey 303 309 7129 7135 O
clinical 310 318 7136 7144 O
benefit 319 326 7145 7152 O
and/or 327 333 7153 7159 O
are 334 337 7160 7163 O
not 338 341 7164 7167 O
suitable 342 350 7168 7176 O
options 351 358 7177 7184 O
per 359 362 7185 7188 O
the 363 366 7189 7192 O
treating 367 375 7193 7201 O
physician 376 385 7202 7211 O
's 385 387 7211 7213 O
judgment 388 396 7214 7222 O

Participants 0 12 7223 7235 O
with 13 17 7236 7240 O
hematologic 18 29 7241 7252 B-cancer
malignancies 30 42 7253 7265 I-cancer

Participants 0 12 7266 7278 O
with 13 17 7279 7283 O
symptomatic 18 29 7284 7295 B-chronic_disease
bradycardia 30 41 7296 7307 I-chronic_disease

Positive 0 8 7308 7316 O
human 9 14 7317 7322 B-chronic_disease
immunodeficiency 15 31 7323 7339 I-chronic_disease
virus 32 37 7340 7345 I-chronic_disease
( 38 39 7346 7347 I-chronic_disease
HIV 39 42 7347 7350 I-chronic_disease
) 42 43 7350 7351 I-chronic_disease
test 44 48 7352 7356 O
, 48 49 7356 7357 O
active 50 56 7358 7364 O
hepatitis 57 66 7365 7374 B-chronic_disease
B 67 68 7375 7376 I-chronic_disease
virus 69 74 7377 7382 I-chronic_disease
( 75 76 7383 7384 I-chronic_disease
HBV 76 79 7384 7387 I-chronic_disease
) 79 80 7387 7388 I-chronic_disease
infection 81 90 7389 7398 O
, 90 91 7398 7399 O
active 92 98 7400 7406 B-chronic_disease
hepatitis 99 108 7407 7416 I-chronic_disease
C 109 110 7417 7418 I-chronic_disease
virus 111 116 7419 7424 I-chronic_disease
( 117 118 7425 7426 I-chronic_disease
HCV 118 121 7426 7429 I-chronic_disease
) 121 122 7429 7430 I-chronic_disease
infection 123 132 7431 7440 O
or 133 135 7441 7443 O
active 136 142 7444 7450 O
tuberculosis 143 155 7451 7463 B-chronic_disease

Pregnant 0 8 7464 7472 B-pregnancy
or 9 11 7473 7475 O
breastfeeding 12 25 7476 7489 O
women 26 31 7490 7495 B-gender
, 31 32 7495 7496 O
or 33 35 7497 7499 O
intending 36 45 7500 7509 O
to 46 48 7510 7512 O
become 49 55 7513 7519 B-pregnancy
pregnant 56 64 7520 7528 I-pregnancy
during 65 71 7529 7535 O
the 72 75 7536 7539 O
study 76 81 7540 7545 O

Presence 0 8 7546 7554 O
of 9 11 7555 7557 O
any 12 15 7558 7561 O
of 16 18 7562 7564 O
the 19 22 7565 7568 O
following 23 32 7569 7578 O
conditions 33 43 7579 7589 O
, 43 44 7589 7590 O
which 45 50 7591 7596 O
are 51 54 7597 7600 O
risk 55 59 7601 7605 O
factors 60 67 7606 7613 O
for 68 71 7614 7617 O
RVO 72 75 7618 7621 B-chronic_disease
: 75 76 7621 7622 O
Uncontrolled 77 89 7623 7635 O
glaucoma 90 98 7636 7644 B-chronic_disease
with 99 103 7645 7649 O
intraocular 104 115 7650 7661 B-clinical_variable
pressure 116 124 7662 7670 I-clinical_variable
> 125 126 7671 7672 O
21 126 128 7672 7674 B-lower_bound
millimetres 129 140 7675 7686 I-lower_bound
of 141 143 7687 7689 I-lower_bound
mercury 144 151 7690 7697 I-lower_bound
( 152 153 7698 7699 I-lower_bound
mm 153 155 7699 7701 I-lower_bound
Hg 156 158 7702 7704 I-lower_bound
) 158 159 7704 7705 I-lower_bound
; 159 160 7705 7706 O
Serum 161 166 7707 7712 B-clinical_variable
cholesterol 167 178 7713 7724 I-clinical_variable
≥Grade 179 185 7725 7731 O
2 186 187 7732 7733 I-lower_bound
; 187 188 7733 7734 O
Hypertriglyceridemia 189 209 7735 7755 B-clinical_variable
≥Grade 210 216 7756 7762 O
2 217 218 7763 7764 O
; 218 219 7764 7765 O
Hyperglycemia 220 233 7766 7779 B-clinical_variable
( 234 235 7780 7781 I-clinical_variable
fasting 235 242 7781 7788 I-clinical_variable
) 242 243 7788 7789 I-clinical_variable
≥Grade 244 250 7790 7796 O
2 251 252 7797 7798 O
; 252 253 7798 7799 O
Grade 254 259 7800 7805 O
≥2 260 262 7806 7808 O
uncontrolled 263 275 7809 7821 O
hypertension 276 288 7822 7834 B-chronic_disease
( 289 290 7835 7836 O
participants 290 302 7836 7848 O
with 303 307 7849 7853 O
a 308 309 7854 7855 O
history 310 317 7856 7863 O
of 318 320 7864 7866 O
hypertension 321 333 7867 7879 O
controlled 334 344 7880 7890 O
with 345 349 7891 7895 O
anti 350 354 7896 7900 B-treatment
- 354 355 7900 7901 I-treatment
hypertensive 355 367 7901 7913 I-treatment
medication 368 378 7914 7924 I-treatment
to 379 381 7925 7927 O
Grade 382 387 7928 7933 O
< 388 389 7934 7935 O
/=1 389 392 7935 7938 O
are 393 396 7939 7942 O
eligible 397 405 7943 7951 O
) 405 406 7951 7952 O

Previous 0 8 7953 7961 O
treatment 9 18 7962 7971 O
with 19 23 7972 7976 O
alectinib 24 33 7977 7986 B-treatment
or 34 36 7987 7989 O
any 37 40 7990 7993 O
other 41 46 7994 7999 O
ALK 47 50 8000 8003 B-treatment
inhibitor 51 60 8004 8013 I-treatment

Previous 0 8 8014 8022 O
treatment 9 18 8023 8032 B-treatment
with 19 23 8033 8037 O
any 24 27 8038 8041 O
HER2 28 32 8042 8046 B-cancer
- 32 33 8046 8047 O
targeted 33 41 8047 8055 O
therapy 42 49 8056 8063 B-treatment

Previous 0 8 8064 8072 B-treatment
treatment 9 18 8073 8082 I-treatment
with 19 23 8083 8087 I-treatment
atezolizumab 24 36 8088 8100 I-treatment
or 37 39 8101 8103 I-treatment
another 40 47 8104 8111 I-treatment
programmed 48 58 8112 8122 I-treatment
death-1 59 66 8123 8130 I-treatment
( 67 68 8131 8132 I-treatment
PD-1)/PD 68 76 8132 8140 I-treatment
- 76 77 8140 8141 I-treatment
L1 77 79 8141 8143 I-treatment
inhibitor 80 89 8144 8153 I-treatment

Previous 0 8 8154 8162 B-treatment
treatment 9 18 8163 8172 I-treatment
with 19 23 8173 8177 I-treatment
cobimetinib 24 35 8178 8189 I-treatment
or 36 38 8190 8192 O
any 39 42 8193 8196 O
other 43 48 8197 8202 O
mitogen 49 56 8203 8210 B-treatment
- 56 57 8210 8211 I-treatment
activated 57 66 8211 8220 I-treatment
protein 67 74 8221 8228 I-treatment
/ 74 75 8228 8229 I-treatment
extracellular 75 88 8229 8242 I-treatment
signal 89 95 8243 8249 I-treatment
- 95 96 8249 8250 I-treatment
regulated 96 105 8250 8259 I-treatment
kinase 106 112 8260 8266 I-treatment
( 113 114 8267 8268 I-treatment
MEK 114 117 8268 8271 I-treatment
) 117 118 8271 8272 I-treatment
inhibitor 119 128 8273 8282 I-treatment

Previous 0 8 8283 8291 B-treatment
treatment 9 18 8292 8301 I-treatment
with 19 23 8302 8306 I-treatment
erlotinib 24 33 8307 8316 I-treatment
or 34 36 8317 8319 O
any 37 40 8320 8323 O
other 41 46 8324 8329 O
EGFR 47 51 8330 8334 B-treatment
inhibitor 52 61 8335 8344 I-treatment

Previous 0 8 8345 8353 B-treatment
treatment 9 18 8354 8363 I-treatment
with 19 23 8364 8368 O
vemurafenib 24 35 8369 8380 B-treatment
or 36 38 8381 8383 O
any 39 42 8384 8387 O
other 43 48 8388 8393 O
BRAF 49 53 8394 8398 B-treatment
inhibitor 54 63 8399 8408 I-treatment
( 64 65 8409 8410 O
prior 65 70 8410 8415 B-treatment
sorafenib 71 80 8416 8425 I-treatment
is 81 83 8426 8428 O
allowed 84 91 8429 8436 O
) 91 92 8436 8437 O

Previous 0 8 8438 8446 B-treatment
treatment 9 18 8447 8456 I-treatment
with 19 23 8457 8461 I-treatment
vismodegib 24 34 8462 8472 I-treatment
or 35 37 8473 8475 O
any 38 41 8476 8479 O
other 42 47 8480 8485 O
hedgehog 48 56 8486 8494 B-treatment
pathway 57 64 8495 8502 I-treatment
inhibitor 65 74 8503 8512 I-treatment

Prior 0 5 8513 8518 O
allogeneic 6 16 8519 8529 B-treatment
stem 17 21 8530 8534 I-treatment
cell 22 26 8535 8539 I-treatment
or 27 29 8540 8542 O
solid 30 35 8543 8548 B-treatment
organ 36 41 8549 8554 I-treatment
transplantation 42 57 8555 8570 I-treatment

Prior 0 5 8571 8576 O
or 6 8 8577 8579 O
concurrent 9 19 8580 8590 O
malignancy 20 30 8591 8601 B-cancer
with 31 35 8602 8606 O
known 36 41 8607 8612 O
RAS 42 45 8613 8616 B-treatment
mutation 46 54 8617 8625 I-treatment

Prior 0 5 8626 8631 B-treatment
treatment 6 15 8632 8641 I-treatment
with 16 20 8642 8646 O
a 21 22 8647 8648 O
RAF 23 26 8649 8652 B-treatment
inhibitor 27 36 8653 8662 I-treatment

Prior 0 5 8663 8668 B-treatment
treatment 6 15 8669 8678 I-treatment
with 16 20 8679 8683 I-treatment
cluster 21 28 8684 8691 I-treatment
of 29 31 8692 8694 I-treatment
differentiation 32 47 8695 8710 I-treatment
137 48 51 8711 8714 I-treatment
( 52 53 8715 8716 I-treatment
CD137 53 58 8716 8721 I-treatment
) 58 59 8721 8722 I-treatment
agonists 60 68 8723 8731 I-treatment
or 69 71 8732 8734 O
immune 72 78 8735 8741 B-treatment
checkpoint 79 89 8742 8752 I-treatment
blockade 90 98 8753 8761 I-treatment
therapies 99 108 8762 8771 I-treatment

Psychological 0 13 8772 8785 B-chronic_disease
, 13 14 8785 8786 O
familial 15 23 8787 8795 B-chronic_disease
, 23 24 8795 8796 O
sociological 25 37 8797 8809 B-chronic_disease
, 37 38 8809 8810 O
or 39 41 8811 8813 O
geographical 42 54 8814 8826 O
conditions 55 65 8827 8837 O
that 66 70 8838 8842 O
do 71 73 8843 8845 O
not 74 77 8846 8849 O
permit 78 84 8850 8856 O
compliance 85 95 8857 8867 O
with 96 100 8868 8872 O
the 101 104 8873 8876 O
protocol 105 113 8877 8885 O

Pulmonary 0 9 8886 8895 B-chronic_disease
embolism 10 18 8896 8904 I-chronic_disease
within 19 25 8905 8911 O
30 26 28 8912 8914 B-upper_bound
days 29 33 8915 8919 I-upper_bound
prior 34 39 8920 8925 I-upper_bound
to 40 42 8926 8928 O
study 43 48 8929 8934 O
entry 49 54 8935 8940 O

Refractory 0 10 8941 8951 O
nausea 11 17 8952 8958 O
and 18 21 8959 8962 O
vomiting 22 30 8963 8971 O
, 30 31 8971 8972 O
malabsorption 32 45 8973 8986 B-chronic_disease
, 45 46 8986 8987 O
external 47 55 8988 8996 O
biliary 56 63 8997 9004 O
shunt 64 69 9005 9010 O
, 69 70 9010 9011 O
or 71 73 9012 9014 O
significant 74 85 9015 9026 O
bowel 86 91 9027 9032 B-treatment
resection 92 101 9033 9042 I-treatment
that 102 106 9043 9047 O
would 107 112 9048 9053 O
preclude 113 121 9054 9062 O
absorption 122 132 9063 9073 O
of 133 135 9074 9076 O
alectinib 136 145 9077 9086 B-treatment

Refractory 0 10 9087 9097 O
nausea 11 17 9098 9104 B-chronic_disease
and 18 21 9105 9108 O
vomiting 22 30 9109 9117 B-chronic_disease
, 30 31 9117 9118 O
malabsorption 32 45 9119 9132 B-chronic_disease
, 45 46 9132 9133 O
external 47 55 9134 9142 O
biliary 56 63 9143 9150 O
shunt 64 69 9151 9156 O
, 69 70 9156 9157 O
or 71 73 9158 9160 O
significant 74 85 9161 9172 O
bowel 86 91 9173 9178 O
resection 92 101 9179 9188 O
that 102 106 9189 9193 O
would 107 112 9194 9199 O
preclude 113 121 9200 9208 O
absorption 122 132 9209 9219 O
of 133 135 9220 9222 O
erlotinib 136 145 9223 9232 B-treatment

Refractory 0 10 9233 9243 O
nausea 11 17 9244 9250 O
and 18 21 9251 9254 O
vomiting 22 30 9255 9263 O
, 30 31 9263 9264 O
malabsorption 32 45 9265 9278 B-chronic_disease
, 45 46 9278 9279 O
external 47 55 9280 9288 O
biliary 56 63 9289 9296 O
shunt 64 69 9297 9302 O
, 69 70 9302 9303 O
or 71 73 9304 9306 O
significant 74 85 9307 9318 B-treatment
bowel 86 91 9319 9324 I-treatment
resection 92 101 9325 9334 I-treatment
that 102 106 9335 9339 O
would 107 112 9340 9345 O
preclude 113 121 9346 9354 O
absorption 122 132 9355 9365 O
of 133 135 9366 9368 O
vemurafenib 136 147 9369 9380 B-treatment

Refractory 0 10 9381 9391 O
nausea 11 17 9392 9398 O
and 18 21 9399 9402 O
vomiting 22 30 9403 9411 O
, 30 31 9411 9412 O
malabsorption 32 45 9413 9426 B-chronic_disease
, 45 46 9426 9427 O
external 47 55 9428 9436 O
biliary 56 63 9437 9444 O
shunt 64 69 9445 9450 O
, 69 70 9450 9451 O
or 71 73 9452 9454 O
significant 74 85 9455 9466 O
bowel 86 91 9467 9472 B-treatment
resection 92 101 9473 9482 I-treatment
that 102 106 9483 9487 O
would 107 112 9488 9493 O
preclude 113 121 9494 9502 O
absorption 122 132 9503 9513 O
of 133 135 9514 9516 O
vismodegib 136 146 9517 9527 B-treatment

Severe 0 6 9528 9534 O
infection 7 16 9535 9544 B-chronic_disease
within 17 23 9545 9551 O
4 24 25 9552 9553 B-upper_bound
weeks 26 31 9554 9559 I-upper_bound
prior 32 37 9560 9565 I-upper_bound
to 38 40 9566 9568 O
initiation 41 51 9569 9579 O
of 52 54 9580 9582 O
study 55 60 9583 9588 O
treatment 61 70 9589 9598 B-treatment

Significant 0 11 9599 9610 O
cardiovascular 12 26 9611 9625 B-chronic_disease
disease 27 34 9626 9633 I-chronic_disease
, 34 35 9633 9634 O
such 36 40 9635 9639 O
as 41 43 9640 9642 O
New 44 47 9643 9646 B-clinical_variable
York 48 52 9647 9651 I-clinical_variable
Heart 53 58 9652 9657 I-clinical_variable
Association 59 70 9658 9669 I-clinical_variable
cardiac 71 78 9670 9677 B-chronic_disease
disease 79 86 9678 9685 I-chronic_disease
( 87 88 9686 9687 O
Class 88 93 9687 9692 B-lower_bound
II 94 96 9693 9695 I-lower_bound
or 97 99 9696 9698 O
greater 100 107 9699 9706 O
) 107 108 9706 9707 O
, 108 109 9707 9708 O
myocardial 110 120 9709 9719 B-chronic_disease
infarction 121 131 9720 9730 I-chronic_disease
, 131 132 9730 9731 O
or 133 135 9732 9734 O
cerebrovascular 136 151 9735 9750 B-chronic_disease
accident 152 160 9751 9759 I-chronic_disease
within 161 167 9760 9766 O
3 168 169 9767 9768 B-upper_bound
months 170 176 9769 9775 I-upper_bound
prior 177 182 9776 9781 I-upper_bound
to 183 185 9782 9784 O
initiation 186 196 9785 9795 O
of 197 199 9796 9798 O
study 200 205 9799 9804 O
treatment 206 215 9805 9814 B-treatment
, 215 216 9814 9815 O
unstable 217 225 9816 9824 B-chronic_disease
arrhythmia 226 236 9825 9835 I-chronic_disease
, 236 237 9835 9836 O
or 238 240 9837 9839 O
unstable 241 249 9840 9848 B-chronic_disease
angina 250 256 9849 9855 I-chronic_disease

Treatment 0 9 9856 9865 B-treatment
with 10 14 9866 9870 O
a 15 16 9871 9872 O
live 17 21 9873 9877 O
, 21 22 9877 9878 O
attenuated 23 33 9879 9889 B-treatment
vaccine 34 41 9890 9897 I-treatment
within 42 48 9898 9904 O
4 49 50 9905 9906 B-upper_bound
weeks 51 56 9907 9912 I-upper_bound
prior 57 62 9913 9918 I-upper_bound
to 63 65 9919 9921 O
initiation 66 76 9922 9932 O
of 77 79 9933 9935 O
study 80 85 9936 9941 B-treatment
treatment 86 95 9942 9951 I-treatment
, 95 96 9951 9952 O
or 97 99 9953 9955 O
anticipation 100 112 9956 9968 O
of 113 115 9969 9971 O
need 116 120 9972 9976 O
for 121 124 9977 9980 O
such 125 129 9981 9985 O
a 130 131 9986 9987 O
vaccine 132 139 9988 9995 O
during 140 146 9996 10002 O
the 147 150 10003 10006 O
course 151 157 10007 10013 O
of 158 160 10014 10016 O
the 161 164 10017 10020 O
study 165 170 10021 10026 O
or 171 173 10027 10029 O
within 174 180 10030 10036 O
5 181 182 10037 10038 B-upper_bound
months 183 189 10039 10045 I-upper_bound
after 190 195 10046 10051 I-upper_bound
the 196 199 10052 10055 O
final 200 205 10056 10061 O
dose 206 210 10062 10066 O
of 211 213 10067 10069 O
atezolizumab 214 226 10070 10082 B-treatment

Treatment 0 9 10083 10092 B-treatment
with 10 14 10093 10097 I-treatment
systemic 15 23 10098 10106 I-treatment
immunostimulatory 24 41 10107 10124 I-treatment
agents 42 48 10125 10131 I-treatment
within 49 55 10132 10138 O
4 56 57 10139 10140 B-upper_bound
weeks 58 63 10141 10146 I-upper_bound
or 64 66 10147 10149 O
five 67 71 10150 10154 B-upper_bound
half 72 76 10155 10159 I-upper_bound
- 76 77 10159 10160 I-upper_bound
lives 77 82 10160 10165 I-upper_bound
of 83 85 10166 10168 O
the 86 89 10169 10172 O
drug 90 94 10173 10177 O
( 95 96 10178 10179 O
whichever 96 105 10179 10188 O
is 106 108 10189 10191 O
longer 109 115 10192 10198 O
) 115 116 10198 10199 O
prior 117 122 10200 10205 O
to 123 125 10206 10208 O
randomization 126 139 10209 10222 O

Treatment 0 9 10223 10232 B-treatment
with 10 14 10233 10237 O
systemic 15 23 10238 10246 O
immunosuppressive 24 41 10247 10264 B-treatment
medication 42 52 10265 10275 I-treatment
within 53 59 10276 10282 O
2 60 61 10283 10284 B-upper_bound
weeks 62 67 10285 10290 I-upper_bound
prior 68 73 10291 10296 I-upper_bound
to 74 76 10297 10299 O
initiation 77 87 10300 10310 O
of 88 90 10311 10313 O
study 91 96 10314 10319 O
treatment 97 106 10320 10329 B-treatment
, 106 107 10329 10330 O
or 108 110 10331 10333 O
anticipation 111 123 10334 10346 O
of 124 126 10347 10349 O
need 127 131 10350 10354 O
for 132 135 10355 10358 O
systemic 136 144 10359 10367 O
immunosuppressive 145 162 10368 10385 O
medication 163 173 10386 10396 O
during 174 180 10397 10403 O
the 181 184 10404 10407 O
course 185 191 10408 10414 O
of 192 194 10415 10417 O
the 195 198 10418 10421 O
study 199 204 10422 10427 O

Treatment 0 9 10428 10437 B-treatment
with 10 14 10438 10442 I-treatment
therapeutic 15 26 10443 10454 I-treatment
oral 27 31 10455 10459 I-treatment
or 32 34 10460 10462 I-treatment
IV 35 37 10463 10465 I-treatment
antibiotics 38 49 10466 10477 I-treatment
within 50 56 10478 10484 O
2 57 58 10485 10486 B-upper_bound
weeks 59 64 10487 10492 I-upper_bound
prior 65 70 10493 10498 I-upper_bound
to 71 73 10499 10501 O
initiation 74 84 10502 10512 O
of 85 87 10513 10515 O
study 88 93 10516 10521 O
treatment 94 103 10522 10531 B-treatment

Uncontrolled 0 12 10532 10544 O
concurrent 13 23 10545 10555 O
malignancy 24 34 10556 10566 B-cancer
( 35 36 10567 10568 O
early 36 41 10568 10573 O
stage 42 47 10574 10579 O
is 48 50 10580 10582 O
allowed 51 58 10583 10590 O
if 59 61 10591 10593 O
not 62 65 10594 10597 O
requiring 66 75 10598 10607 O
active 76 82 10608 10614 O
therapy 83 90 10615 10622 B-treatment
or 91 93 10623 10625 O
intervention 94 106 10626 10638 O
) 106 107 10638 10639 O

Uncontrolled 0 12 10640 10652 O
or 13 15 10653 10655 O
symptomatic 16 27 10656 10667 O
hypercalcemia 28 41 10668 10681 B-chronic_disease

Uncontrolled 0 12 10682 10694 O
pleural 13 20 10695 10702 B-chronic_disease
effusion 21 29 10703 10711 I-chronic_disease
, 29 30 10711 10712 O
pericardial 31 42 10713 10724 B-chronic_disease
effusion 43 51 10725 10733 I-chronic_disease
, 51 52 10733 10734 O
or 53 55 10735 10737 O
ascites 56 63 10738 10745 O
requiring 64 73 10746 10755 O
recurrent 74 83 10756 10765 O
drainage 84 92 10766 10774 O
procedures 93 103 10775 10785 O
( 104 105 10786 10787 O
once 105 109 10787 10791 B-lower_bound
monthly 110 117 10792 10799 I-lower_bound
or 118 120 10800 10802 O
more 121 125 10803 10807 O
frequently 126 136 10808 10818 O
) 136 137 10818 10819 O
. 137 138 10819 10820 O
Patients 139 147 10821 10829 O
with 148 152 10830 10834 O
indwelling 153 163 10835 10845 O
catheters 164 173 10846 10855 O
are 174 177 10856 10859 O
allowed 178 185 10860 10867 O

Uncontrolled 0 12 10868 10880 O
tumor 13 18 10881 10886 B-cancer
pain 19 23 10887 10891 O

